Written by Yasmin Tarfi Labouri
In the world of healthcare, pharmaceutical innovation is like a powerful, unseen current, constantly pushing medicine to new frontiers and expanding what’s achievable. This kind of innovation isn’t just about labs and test tubes; it touches on a wide array of scientific, medical, economic, and social aspects (IPC Public Debates, n.d.). Think of pharmaceutical innovation as a multi-faceted process. It includes the discovery, development, production, and supply of new treatments. But it also involves finding fresh approaches to sourcing materials and forging partnerships, all aimed at making medical products more widely available and easier for people to access (IPC Public Debates, n.d.).
Europe is a significant hub for this pharmaceutical innovation, holding about 24.5% of the global market share. However, there’s a noticeable gap: major pharmaceutical companies (often called “Big Pharma”) have a smaller footprint in regions that critically need these medical advancements, particularly in the African continent. This leads to a striking paradox in Africa. The continent bears a heavy burden of global infectious and chronic diseases, yet it remains largely on the sidelines when it comes to pharmaceutical innovation. Major players in the industry tend to invest in markets where the financial returns on R&D are more predictable, leaving many specific health needs of the African population unmet.
Given this reality, it’s crucial to think about how pharmaceutical innovation strategies can be better tailored to the diverse situations across different areas of this continent. Among the health issues most affected by these gaps, breast cancer in sub-Saharan Africa stands out as a particularly alarming example. The number of cases (its incidence) continues to climb. Yet, major pharmaceutical companies often keep their R&D focus on more profitable markets, neglecting the specific requirements of this population (SciDev.Net, 2022). Beyond just treatment, access to diagnosis is a major hurdle. A World Health Organization (WHO) study identified late diagnosis as a key barrier to effective breast cancer treatment. Tragically, in sub-Saharan Africa, the survival rate for breast cancer is alarmingly low: less than 50% of patients live five years beyond their diagnosis, meaning one in two women diagnosed succumbs to the disease within that timeframe (IARC, 2023).
In this challenging landscape, the work of Roche, a Swiss company founded in 1896, offers a relevant case study. Today, Roche is one of the world’s leading biotechnology giants, active in both pharmaceuticals and diagnostics, with a core mission to improve patients’ lives through research and innovation (Roche, n.d.). Their commitment to tackling breast cancer is especially noteworthy, particularly as the disease’s incidence is rapidly increasing in sub-Saharan Africa. Their well-known treatment, Trastuzumab (Herceptin), has revolutionized the management of HER2+ breast cancer, though getting this treatment to patients in low-income countries still faces significant economic and structural obstacles (Roche, n.d.).
To tackle these challenges, Roche is leveraging technological innovation, especially by improving access to advanced diagnostic tools. A key development has been the introduction of mobile mammography units. Working with local authorities, Roche is deploying mobile clinics equipped with digital mammography machines. This allows for early screening in rural areas, reaching more patients and speeding up the examination process (Roche, 2021). Mammography itself is a medical imaging technique using low-dose X-rays to examine breast tissue. A special machine gently compresses the breast to capture high-quality images, which are then analyzed by a radiologist to detect abnormalities like lumps or microcalcifications (Roche, 2021). The innovative edge here is the ability to overcome physical barriers to diagnosis in rural areas in sub-Saharan Africa. By bringing screening equipment closer to remote populations and making it more transportable, Roche enables earlier disease detection, which can reduce diagnoses at late, more dangerous stages, a major factor in sub-Saharan Africa’s high breast cancer mortality rates (Roche, 2021).
Furthermore, the use of cutting-edge technologies in these mobile units represents a significant step forward. Roche is incorporating artificial intelligence (AI) and telemedicine solutions to enhance real-time analysis of results. This allows specialists to interpret medical images remotely and provide swift diagnoses, a crucial innovation in countries with shortages of radiologists and oncologists, thereby broadening access to expert medical opinions (Roche & Jhpiego, 2022). Roche’s innovative drive doesn’t stop at analysis algorithms; they are also investing in DNA screening and biomarker technologies, especially in sub-Saharan Africa. The company collaborates with African research institutes to develop molecular and genomic tests that can identify genetic mutations specific to breast cancer in African patients. This
approach helps pave the way for more personalized treatments tailored to each patient’s unique biology, boosting the effectiveness and precision of breast cancer care.
For instance, an epidemiological study in Benin found that breast cancer is the most common cancer among women, with a median diagnosis age of 48. Notably, the triple-negative molecular type, a particularly aggressive form, accounted for 32% of cases (Sanni-Ali et al., 2021). Such data underscore the importance of genetic research in adapting treatments to the specific needs of these patients.
In its pursuit of innovation, Roche aims to develop breast cancer treatment options that consider the realities and challenges unique to the sub-Saharan Africa context. For example, they are working on long-acting injectable versions of their drugs. This would reduce how often patients need to receive medication and limit the number of clinic visits, a significant benefit given the often-limited healthcare infrastructure in many parts of the studied region. This approach makes it easier for patients to stick to their treatment plans and improves their quality of life.
We’ve seen how vital pharmaceutical and technological innovation is and the key role it plays in improving healthcare access, especially in Africa. True innovation goes beyond just discovering new treatments; it also involves making them accessible, distributing them effectively, and adapting them to local conditions. As a major industry player, Roche has developed various strategies to address the needs of this market, this example illustrates that tailoring innovation to the specific needs and local realities of each population is not only a highly effective strategy but an absolutely necessary one for achieving tangible progress. These initiatives demonstrate that innovation can be a powerful force for transforming the medical landscape and offering new hope for patients battling serious diseases.
Bibliography
International Agency for Research on Cancer (IARC). (2023). Survival rates of breast cancer patients in Africa. Retrieved from https://www.iarc.who.int/research/cancer-burden-africa
IPC Public Debates. (n.d.). Pharmaceutical innovation and its economic and social impacts. Retrieved from https://www.debatspublics-ipc.fr/innovation-pharmaceutique
Roche. (n.d.). Our innovation process. Roche. Retrieved from https://www.roche.com/innovation/process
Roche. (n.d.). Our strategy. Roche. Retrieved from https://www.roche.com/about/strategy
Roche. (2021). Technological innovations in Africa: Mobile mammography and artificial intelligence. Retrieved from https://www.roche.com/mammography-africa-ai
Roche & Jhpiego. (2022). Partnerships to improve healthcare in Africa. Retrieved from https://www.roche.com/partnerships-healthcare-africa
Sanni-Ali, A., et al. (2021). Epidemiology of breast cancer in Benin: Molecular subtypes and survival rates. Retrieved from https://journals.sagepub.com/doi/full/10.1177/09691413211036534 ● SciDev.Net. (2022). Healthcare R&D spending in Africa: The 1% challenge. Retrieved from https://www.scidev.net/global/healthcare-rd-africa
Astra Stem 
Leave a comment